Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04224181 · ClinicalTrials.gov registry record
Inflammation and Cardiovascular Health in Women
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 62
- Enrollment target
NCT04224181: Completed study, sponsored by Massachusetts General Hospital.
NCT04224181 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04224181 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 62 participants
- Enrollment target
Study Summary
Systemic immune activation and inflammation are believed to play a significant role in the development and clinical course of myocardial infarction (MI). Among women with HIV (WHIV), heightened systemic immune activation and inflammation persist, even when HIV infection is well-treated with contemporary antiretroviral therapeutic regimens. Moreover, WHIV in high-resource regions face a three-fold increased risk of myocardial infarction as compared with matched non-HIV-infected women. The goals of this study are to better understand ways in which HIV infection-incited systemic immune activation and inflammation augment MI risk among women.
Interventions
- RADIATION Cardiac PET
- RADIATION 99mTc-tilmanocept SPECT/CT
- RADIATION Contrast Enhanced Coronary and Aortic Computed Tomography Angiography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2020-02-03 |
| Est. Completion | 2023-11-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04224181
The ClinicalTrials.gov registry entry for NCT04224181 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cardiac PET is the first listed.
NCT04224181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04224181 about?
NCT04224181 is a clinical study titled "Inflammation and Cardiovascular Health in Women". Systemic immune activation and inflammation are believed to play a significant role in the development and clinical course of myocardial infarction (MI). Among women with HIV (WHIV), heightened systemic immune activation and inflammation persist, even when HIV infection is well-treated with contempo...
What is the current status of trial NCT04224181?
This trial is currently completed. The enrollment target is 62 participants. The study started on 2020-02-03. Estimated completion is 2023-11-09.
What interventions are being tested in trial NCT04224181?
The interventions under investigation include: Cardiac PET (RADIATION), 99mTc-tilmanocept SPECT/CT (RADIATION), Contrast Enhanced Coronary and Aortic Computed Tomography Angiography (RADIATION).
Who is sponsoring clinical trial NCT04224181?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.